Last updated on October 2006

IVIG in the Treatment of Metastatic Cancers of the Prostate Colon and Melanoma


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.

Detailed Study Description

This study is a one arm, open label, multi-center, phase II study. Its aim is to evaluate the safety and efficacy of IVIG administered as treatment for metastasis solid tumors. IVIG was proven as affecting the growth of tumor metastasis in animals’ models. Study population is including male or female, 18 and older, diagnosed as having a primary tumor (colon, melanoma or prostate) with measurable metastasis (according to the RECIST criteria) in soft tissues and/ or tumor markers in prostate cancer, for which there is no better alternate treatment. The patients receive the IVIG calculated as 1g/kg/bodyweight per cycle (defined as every 21 days) until progression disease is noted. All patients are being followed for a period of 6 months after patient’s withdrawal.

Clinical Study Identifier: NCT00294476

Contact Investigators or Research Sites near you

Start Over

Jacob Schachter, M.D.

Ella Institute, Oncology institute, Sheba Medical Center
Tel Hashomer, Israel
  Connect »

Dan Aderka, M.D

Oncology Institute, Sheba Medical Center
Tel Hashomer, Israel
  Connect »

Alberto Gabison, M.D.

Oncology institute, Shaare Zedek Medical Center
Jerusalem, Israel
  Connect »